Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

ClinicalTrials.gov ID: NCT01469039

Public ClinicalTrials.gov record NCT01469039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia

Study identification

NCT ID
NCT01469039
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
623 participants

Conditions and interventions

Conditions

Interventions

  • ALKS 9072 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2011
Primary completion
Dec 31, 2013
Completion
Feb 28, 2014
Last update posted
Jan 29, 2019

2011 – 2014

United States locations

U.S. sites
26
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72201
Alkermes Investigational Site Little Rock Arkansas 72211
Alkermes Investigational Site Springdale Arkansas 72764
Alkermes Investigational Site Cerritos California 90703
Alkermes Investigational Site Garden Grove California 92845
Alkermes Investigational Site La Habra California 90631
Alkermes Investigational Site Oakland California 94612
Alkermes Investigational Site Oceanside California 92056
Alkermes Investigational Site Orange California 92868
Alkermes Investigational Site San Diego California 92123
Alkermes Investigational Site Washington D.C. District of Columbia 20016
Alkermes Investigational Site Fort Lauderdale Florida 33308
Alkermes Investigational site Leesburg Florida 34748
Alkermes Investigational Site Atlanta Georgia 30308
Alkermes Investigational Site Chicago Illinois 60640
Alkermes Investigational Site Hoffman Estates Illinois 60169
Alkermes Investigational Site Overland Park Kansas 66212
Alkermes Investigational Site Rockville Maryland 20850
Alkermes Investigational Site Creve Coeur Missouri 63141
Alkermes Investigational Site St Louis Missouri 63118
Alkermes Investigational Site Philadelphia Pennsylvania 19139
Alkermes Investigational Site Charleston South Carolina 29407
Alkermes Investigational Site Austin Texas 78731
Alkermes Investigational Site Austin Texas 78754
Alkermes Investigational Site Dallas Texas 75231
Alkermes Investigational Site Dallas Texas 75243

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01469039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2019 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01469039 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →